Wolfram syndrome is a rare genetic condition that demands specialized medical care throughout a person’s lifetime. Because symptoms appear gradually and affect many parts of the body, treatment focuses on managing each complication as it develops, preserving quality of life, and slowing disease progression wherever possible. While no cure currently exists, researchers around the world are actively testing innovative therapies in clinical trials that offer hope for the future.

Understanding the Goals of Treatment in Wolfram Syndrome

When healthcare providers work with patients who have Wolfram syndrome, the main goal is not simply to address one isolated symptom. Instead, treatment seeks to support as many body systems as possible while reducing the burden of daily challenges these individuals face. This means helping to control blood sugar levels, protecting remaining vision and hearing, managing urinary and neurological problems, and supporting mental and emotional wellbeing.^[1][4]

Because Wolfram syndrome typically begins in childhood with diabetes mellitus—a condition where the body cannot properly regulate blood sugar—early treatment usually revolves around insulin therapy. However, as time goes on, other symptoms emerge in a somewhat predictable pattern. Vision loss due to optic atrophy, which is the breakdown of the nerve that carries signals from the eye to the brain, often follows. Then hearing loss and a condition called diabetes insipidus, where the body loses too much water through excessive urination, may develop.^[1][2]

Each symptom requires its own specific care plan. The treatment approach must adapt as the disease progresses, and healthcare teams often include specialists from multiple fields such as endocrinology, ophthalmology, audiology, neurology, and urology. This multidisciplinary approach is essential because Wolfram syndrome is not just one problem—it is a collection of interconnected challenges that unfold over years.^[4][6]

Standard Treatment Options for Managing Symptoms

Controlling Diabetes Mellitus

The most common first symptom in Wolfram syndrome is diabetes mellitus, which usually appears around age six. Unlike type 1 diabetes, which is caused by the immune system attacking insulin-producing cells in the pancreas, Wolfram syndrome-related diabetes is not autoimmune in nature. However, it is treated similarly to type 1 diabetes. Patients require insulin therapy because their pancreas does not produce enough of this hormone to keep blood sugar levels stable.^[1][3]

Insulin can be delivered through multiple daily injections or via an insulin pump, a small device that delivers insulin continuously throughout the day. Patients and caregivers must regularly monitor blood glucose levels using finger-prick tests or continuous glucose monitoring devices. Keeping blood sugar as close to normal as possible is important because high glucose levels can add stress to already vulnerable cells in the body, potentially worsening other symptoms over time.^[7][3]

People with Wolfram syndrome often need less insulin than those with classic type 1 diabetes, and they may experience more frequent episodes of low blood sugar, known as hypoglycemia. This requires careful adjustment of insulin doses and close communication with an endocrinologist. Some patients may benefit from medications used for type 2 diabetes, such as agents that help the body use insulin more effectively, though this is decided on a case-by-case basis.^[3]

Managing Diabetes Insipidus

Around 70 percent of people with Wolfram syndrome type 1 eventually develop diabetes insipidus, typically around age 14. Despite the similar name, this condition has nothing to do with blood sugar. Instead, it involves the pituitary gland, a small structure at the base of the brain that normally releases a hormone called vasopressin. This hormone tells the kidneys how much water to retain in the body. When vasopressin production is disrupted, the kidneys release too much water, causing excessive urination and severe thirst.^[1][2]

Treatment for diabetes insipidus involves replacing the missing hormone with a synthetic version called desmopressin. This medication can be taken as a nasal spray, tablet, or injection. It reduces urine output and helps the body maintain proper fluid balance. Without treatment, diabetes insipidus can lead to dehydration, electrolyte imbalances, and constant disruption of daily life due to the need to urinate frequently, even at night.^[7][16]

Addressing Vision Loss

Optic atrophy, or the degeneration of the optic nerve, is a hallmark feature of Wolfram syndrome and typically develops around age 11. The first signs are often loss of color vision and reduced side vision. Over time, central vision also deteriorates, and many patients become legally blind within approximately eight years of the onset of visual symptoms.^[2][3]

Unfortunately, there is currently no treatment that can stop or reverse optic atrophy in Wolfram syndrome. However, regular eye examinations by an ophthalmologist are crucial to monitor progression and provide supportive care. Visual aids such as magnifying devices, screen readers, and mobility training can help individuals adapt to vision loss and maintain independence for as long as possible. Some patients may benefit from low-vision rehabilitation services that teach strategies for daily activities.^[16][7]

Managing Hearing Loss

Approximately 65 percent of people with Wolfram syndrome experience sensorineural hearing loss, which results from damage to the inner ear structures. This type of hearing loss can begin at birth or develop gradually during adolescence, and it tends to worsen over time. Initially, it may affect only high-frequency sounds or make it difficult to hear in noisy environments.^[2][3]

Treatment involves the use of hearing aids or, in more severe cases, cochlear implants—devices that bypass damaged parts of the ear and directly stimulate the auditory nerve. Regular hearing assessments by an audiologist are essential to adjust these devices as hearing continues to decline. Speech therapy may also be helpful, especially for children, to support language development and communication skills.^[7][16]

Addressing Urinary and Bladder Problems

Between 60 and 90 percent of individuals with Wolfram syndrome develop urinary tract problems. These can include a bladder that becomes overly large and unable to empty properly, obstruction of the tubes that carry urine from the kidneys to the bladder, difficulty controlling urination, and frequent urinary tract infections.^[2][3]

Treatment may involve medications that help the bladder contract or relax as needed. In some cases, patients need to use catheterization, which involves inserting a thin tube into the bladder to drain urine. This can be done intermittently throughout the day or continuously via a permanent catheter. Physical therapy focusing on pelvic floor muscles and working with a urologist can help manage these symptoms and reduce the risk of complications such as kidney damage.^[16][10]

Neurological and Psychiatric Support

Approximately 60 percent of people with Wolfram syndrome develop neurological or psychiatric symptoms, often beginning in early adulthood. These can include problems with balance and coordination, muscle spasms, seizures, reduced sensation in the legs and feet, and difficulty with memory and thinking. Psychiatric issues such as depression, anxiety, impulsive behavior, and in some cases psychosis, can also occur.^[2][3]

Treatment is tailored to the specific symptoms. Medications such as antidepressants, mood stabilizers, or anti-seizure drugs may be prescribed. Physical therapy and occupational therapy can help with balance, coordination, and daily living skills. Counseling and psychological support are vital, as the emotional burden of a progressive, life-limiting illness is immense for both patients and families. Some individuals benefit from cognitive behavioral therapy or other forms of mental health intervention.^[16][10]

Other Supportive Treatments

Patients with Wolfram syndrome may experience a range of additional complications, including gastrointestinal problems, difficulty regulating body temperature, chronic fatigue, and breathing difficulties. In advanced stages, some individuals develop central sleep apnea or problems with swallowing, which can increase the risk of choking or respiratory failure. These symptoms require close monitoring and sometimes interventions such as breathing support devices, feeding tubes, or medications to manage specific issues.^[3][10]

Nutritional support is also important. A dietitian can help tailor meal plans to manage diabetes while ensuring adequate calorie and nutrient intake, especially if eating becomes difficult due to neurological problems. Regular follow-up appointments with a multidisciplinary team are essential to catch new symptoms early and adjust the care plan as needed.^[6]

Promising Therapies Being Tested in Clinical Trials

Although standard treatments can help manage the symptoms of Wolfram syndrome, they do not address the underlying cause of the disease or slow its progression. Researchers are working urgently to develop therapies that target the root biological problems in Wolfram syndrome. Because the condition is caused by mutations in specific genes—most commonly the WFS1 gene, and less often the CISD2 gene—scientists have a clear biological target for new treatments.^[4][6]

Understanding the Disease Mechanism

The WFS1 gene provides instructions for making a protein called wolframin, which is located in a part of the cell called the endoplasmic reticulum (ER). The ER is responsible for folding proteins correctly and maintaining calcium balance inside cells. When wolframin is missing or defective, the ER becomes stressed, and cells—especially those in the pancreas, eyes, inner ear, and brain—begin to malfunction and die. This process is called ER stress, and Wolfram syndrome is considered a model disease for studying how ER stress leads to cell death.^[5][14]

Understanding this mechanism has opened the door to several potential treatment strategies. Researchers are investigating ways to reduce ER stress, improve mitochondrial function (the energy-producing parts of cells), protect remaining cells from death, and even replace lost cells through regenerative approaches.^[6][11]

AMX0035: Targeting ER Stress and Mitochondrial Dysfunction

One of the most advanced investigational treatments for Wolfram syndrome is a compound called AMX0035. This is a combination of two small molecules designed to reduce both ER stress and mitochondrial dysfunction, the two main processes that lead to cell death in Wolfram syndrome.^[5][14]

In preclinical studies using cells derived from patients with Wolfram syndrome, AMX0035 improved the expression of the WFS1 protein, increased insulin secretion from pancreatic beta cells, and prevented cell death in both beta cells and neurons. In animal models lacking the WFS1 gene, treatment with AMX0035 significantly delayed the onset of diabetes.^[5][14]

Based on these promising results, a Phase 2 clinical trial called HELIOS was conducted in the United States. This was an open-label, single-arm study involving 12 adult participants with Wolfram syndrome. The primary goal was to evaluate the safety and tolerability of AMX0035 while also measuring its effects on pancreatic function, neurological symptoms, and vision.^[5][13]

Results presented in 2025 showed that treatment with AMX0035 led to sustained improvement in pancreatic beta cell function at both 24 and 48 weeks, as measured by a test called C-peptide response to a mixed-meal tolerance test. This is significant because preserving beta cell function could help patients maintain better blood sugar control and reduce their dependence on high doses of insulin. Patients also showed stabilization or improvement in blood sugar control (measured by hemoglobin A1c and continuous glucose monitoring) and visual acuity.^[5][14]

All participants who completed assessments reported either improvement or no worsening in their overall Wolfram syndrome symptoms, as measured by both patient and clinician global impression scales. Importantly, the drug was well tolerated, with all side effects being mild to moderate and no serious adverse events related to the treatment.^[5][14]

The U.S. Food and Drug Administration (FDA) granted AMX0035 Orphan Drug Designation for Wolfram syndrome in November 2020, and the European Commission followed in August 2024. This designation helps speed up the development and approval process for treatments for rare diseases. Researchers are now planning a Phase 3 trial, which will involve more participants and directly compare the drug to a placebo or standard care to definitively determine its effectiveness.^[5][14]

Dantrolene: Stabilizing Calcium Levels in Cells

Another promising treatment approach involves repurposing an existing FDA-approved drug called dantrolene. This medication is normally used to treat muscle spasms and a dangerous condition called malignant hyperthermia, which can occur during surgery. However, researchers discovered that dantrolene also stabilizes calcium levels in the ER, which is disrupted in Wolfram syndrome.^[12]

In laboratory studies, dantrolene was able to suppress cell death and dysfunction in mouse models of Wolfram syndrome. It also prevented cell death in neural progenitor cells derived from patients with the condition. These findings led to a Phase 1b/2 clinical trial conducted at Washington University School of Medicine in St. Louis, Missouri. The study enrolled both pediatric and adult patients with Wolfram syndrome to assess the safety, tolerability, and efficacy of dantrolene.^[12]

The trial, which began in January 2017, evaluated not only whether the drug was safe but also whether it had any impact on visual acuity, remaining beta cell function, and neurological symptoms. The study has been completed, and while full results have not been widely published, early findings suggested that the drug was generally safe and showed potential benefits in stabilizing disease progression.^[12]

MANF: A Regenerative Approach

Another exciting area of research involves a naturally occurring protein called mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF is known to protect cells from ER stress-related death and may even help damaged cells recover. Studies have shown that MANF and its signaling pathways can protect neurons, pancreatic beta cells, and retinal ganglion cells—all of which are affected in Wolfram syndrome.^[12]

In preclinical studies, researchers administered MANF protein or used gene therapy with adeno-associated virus (AAV) vectors to deliver the MANF gene to cells in Wolfram mouse models. The results were encouraging: MANF induced proliferation of remaining beta cells, suggesting it could help restore some pancreatic function. Researchers are also testing whether MANF can prevent or slow retinal degeneration in models of Wolfram syndrome.^[12]

While this approach is still in the early stages of development, it represents a potential regenerative medicine strategy that could not only slow disease progression but potentially reverse some of the damage already done.^[11]

Second-Generation ER Calcium Stabilizers

Researchers are also developing new small molecules that work similarly to dantrolene but are more potent, safer, and better able to reach the brain and nervous system. These second-generation ER calcium stabilizers target the same cellular pathways but are designed to be more effective in the specific context of Wolfram syndrome.^[12]

In laboratory and cell-based studies, these new compounds have shown the ability to prevent cell death in both beta cells and neurons derived from patients with Wolfram syndrome. Although these drugs are still in preclinical development and have not yet been tested in humans, they represent an important part of the treatment pipeline.^[12]

GLP-1 Receptor Agonists

Another class of drugs being explored are GLP-1 receptor agonists, such as dulaglutide. These medications are commonly used to treat type 2 diabetes because they help the pancreas release more insulin in response to meals and protect beta cells from damage. Researchers have tested dulaglutide in mouse models and in beta cells derived from patients with Wolfram syndrome.^[13]

Results showed improved glucose tolerance in the animal models and improved beta cell function in the lab-grown cells. These findings suggest that GLP-1 receptor agonists might help preserve pancreatic function in people with Wolfram syndrome, though clinical trials in humans are needed to confirm this potential benefit.^[13]

Gene Therapy and Future Directions

Because Wolfram syndrome is caused by mutations in a single gene, it is an ideal candidate for gene therapy—a treatment approach that involves delivering a correct copy of the WFS1 or CISD2 gene into cells to restore normal protein production. While gene therapy for Wolfram syndrome is still in the experimental stage, advances in gene delivery technologies, such as AAV vectors, make this a realistic goal for the future.^[11]

Researchers are also exploring the use of induced pluripotent stem cells (iPSCs) derived from patients with Wolfram syndrome. These cells can be turned into any type of cell in the body, including beta cells and neurons, allowing scientists to study the disease in the lab and test potential treatments in a personalized way.^[13]

Where Clinical Trials Are Taking Place

Most clinical trials for Wolfram syndrome have been conducted in the United States, particularly at Washington University School of Medicine in St. Louis, which hosts the International Wolfram Syndrome Registry and Clinic. This center has been at the forefront of research and patient care for Wolfram syndrome for many years.^[13]

Some research and patient registries also exist in Europe and other parts of the world. Families interested in participating in clinical trials should speak with their healthcare providers or contact specialized centers directly to learn about eligibility and enrollment opportunities.^[6]

Most Common Treatment Methods

• Insulin therapy
  • Multiple daily injections or insulin pump for managing diabetes mellitus
  • Requires regular blood glucose monitoring to adjust doses
  • Helps prevent high blood sugar from stressing vulnerable cells
• Hormone replacement
  • Desmopressin for diabetes insipidus to reduce excessive urination
  • Available as nasal spray, tablet, or injection
  • Prevents dehydration and electrolyte imbalances
• Visual and hearing aids
  • Magnifying devices, screen readers, and mobility training for vision loss
  • Hearing aids or cochlear implants for sensorineural hearing loss
  • Regular monitoring by ophthalmologist and audiologist
• Urological management
  • Medications to help bladder function properly
  • Intermittent or continuous catheterization if needed
  • Close monitoring to prevent kidney complications
• Neurological and psychiatric support
  • Antidepressants, mood stabilizers, or anti-seizure medications as needed
  • Physical and occupational therapy for balance and coordination
  • Counseling and psychological support for patients and families
• Experimental therapies in clinical trials
  • AMX0035: combination therapy targeting ER stress and mitochondrial dysfunction, showing positive results in Phase 2 trials
  • Dantrolene: repurposed drug that stabilizes cellular calcium levels, tested in Phase 1b/2 trial
  • MANF protein therapy: regenerative approach being studied in preclinical models
  • GLP-1 receptor agonists: diabetes drugs tested for protecting pancreatic beta cells
  • Second-generation ER calcium stabilizers: new molecules in preclinical development